Regorafenib Alone or in Combination With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer (SLOT)
Microsatellite Stable Metastatic Colorectal Cancer
About this trial
This is an interventional treatment trial for Microsatellite Stable Metastatic Colorectal Cancer
Eligibility Criteria
Inclusion Criteria: Age ≥18 years old An Eastern Cooperative Oncology Group (ECOG) performance status ≤1 Life expectancy of at least 3 months Histopathological confirmed MSS/pMMR adenocarcinoma of the colon or rectum At least two evaluable metastatic lesions for SABR and LDRT according to RECIST 1.1 Progressed on or after the standard first-and second-line therapies or stopped standard therapy because of unacceptable toxic effects Previous radiotherapy completed at least 4 weeks before randomization Adequate bone-marrow, hepatic, and renal function: neutrophils ≥ 1.5 × 10^9/L, Hb ≥ 90 g/L, PLT ≥ 100 × 10^9/L, ALT/ AST≤2.5 ULN, Cr≤1 ULN Sign the informed consent and have good compliance Exclusion Criteria: History of previous treatment with regorafenib and ICIs such as anti-PD-1 or anti-PD-L1 mAbs Current severe cardiovascular diseases such as unstable angina, congestive heart failure, or serious cardiac arrhythmia requiring medication Acute cardiac infarction or cerebral ischemic stroke occurred within 6 months before recruitment Active autoimmune diseases and immunodeficiencies, known history of organ transplantation, or systematic use of immunosuppressive agents Active Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection: HBsAg positive or HBV DNA positive, anti-HCV antibody testing positive and confirmatory HCV RNA positive Positive human immunodeficiency virus (HIV) infection, active syphilis infection, or active pulmonary tuberculosis infection Severe infections requiring systemic antibiotics, antifungal or antiviral therapy Uncontrollable pleural effusion, pericardial effusion, or ascites Other malignancies within 5 years before recruitment, except for non-melanoma skin cancer, superficial bladder cancer, cervical carcinoma in situ, or breast cancer in situ that had been effectively treated. Known history of severe neurological or mental illness such as schizophrenia, dementia, or epilepsy Known history of allergy to any component involved in this study. Pregnancy or breast-feeding women
Sites / Locations
- Fudan University Shanghai Cancer CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
monotherapy
combination therapies
a total of 45 patients will receive regorafenib monotherapy.
a total of 45 patients will first receive 1 cycle of regorafenib and toripalimab followed by SABR/LDRT radiotherapy. Regorafenib and toripalimab will be continued after the completion of radiotherapy.